A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient’s body and responses to treatment.
Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.
Now, researchers at the Stanford University School of Medicine have devised a way to quickly bring the technique to the clinic. Their approach, which should be broadly applicable to many types of cancers, is highly sensitive and specific. With it they were able to accurately identify about 50 percent of people in the study with stage-1 lung cancer and all patients whose cancers were more advanced.
“We set out to develop a method that overcomes two major hurdles in the circulating tumor DNA field,” said Maximilian Diehn, MD, PhD, the CRK Faculty Scholar and assistant professor of radiation oncology. “First, the technique needs to be very sensitive to detect the very small amounts of tumor DNA present in the blood. Second, to be clinically useful it’s necessary to have a test that works off the shelf for the majority of patients with a given cancer.”
The researchers describe their findings in a paper published online April 6 in Nature Medicine. Diehn shares senior authorship with Ash Alizadeh, MD, PhD, assistant professor of medicine. Postdoctoral scholars Aaron Newman, PhD, and Scott Bratman, MD, PhD share lead authorship.
“We’re trying to develop a general method to detect and measure disease burden,” said Alizadeh, a hematologist and oncologist. “Blood cancers like leukemias can be easier to monitor than solid tumors through ease of access to the blood. By developing a general method for monitoring circulating tumor DNA, we’re in effect trying to transform solid tumors into liquid tumors that can be detected and tracked more easily.”
Even in the absence of treatment, cancer cells are continuously dividing and dying. As they die, they release DNA into the bloodstream, like tiny genetic messages in a bottle. Learning to read these messages — and to pick out the one in 1,000 or 10,000 that come from a cancer cell — can allow clinicians to quickly and noninvasively monitor the volume of tumor, a patient’s response to therapy and even how the tumor mutations evolve over time in the face of treatment or other selective pressures.
“The vast majority of circulating DNA is from normal, non-cancerous cells, even in patients with advanced cancer,” Bratman said. “We needed a comprehensive strategy for isolating the circulating DNA from blood and detecting the rare, cancer-associated mutations. To boost the sensitivity of the technique, we optimized methods for extracting, processing and analyzing the DNA.
The researchers’ technique, which they have dubbed CAPP-Seq, for Cancer Personalized Profiling by deep Sequencing, is sensitive enough to detect just one molecule of tumor DNA in a sea of 10,000 healthy DNA molecules in the blood. Although the researchers focused on patients with non-small-cell lung cancer (which includes most lung cancers, including adenocarcinomas, squamous cell carcinoma and large cell carcinoma), the approach should be widely applicable to many different solid tumors throughout the body. It’s also possible that it could one day be used not just to track the progress of a previously diagnosed patient, but also to screen healthy or at-risk populations for signs of trouble.
Tumor DNA differs from normal DNA by virtue of mutations in the nucleotide sequence. Some of the mutations are thought to be cancer drivers, responsible for initiating the uncontrolled cell growth that is the hallmark of the disease. Others accumulate randomly during repeated cell division. These secondary mutations can sometimes confer resistance to therapy; even a few tumor cells with these types of mutations can expand rapidly in the face of seemingly successful treatment.
Different from patient to patient
“Cancer is a genetic disease,” Alizadeh said. “But unlike Down syndrome, for example, which has a single dominant cause, for most cancers it’s very difficult to identify any one particular genetic aberration or mutation that is found in every patient. Instead, each cancer tends to be genetically different from patient to patient, although sets of mutations can be shared among patients with a given cancer.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- AI Blood Test Can Spot Lung Cancers With 90 Percent Accuracyon August 20, 2021 at 7:41 pm
The tool was able to detect roughly 90 percent of cancer cases out of 800 individuals that were screened for lung cancer. The researchers are hoping that improved screening and detection technologies ...
- New AI blood test found to detect over 90% of lung cancerson August 20, 2021 at 6:43 pm
A novel artificial intelligence blood testing technology developed by researchers at the Johns Hopkins Kimmel Cancer Center was found to detect over 90% of lung cancers in samples from nearly 800 ...
- Delfi Diagnostics' AI-based blood test detects 80% of early-stage lung cancer cases, study findson August 20, 2021 at 7:05 am
While Delfi Diagnostics’ goal of creating a more accurate and affordable method to detect early-stage cancers reflects the aims of its many competitors in the space, it’s taking a different approach ...
- Cancer patients’ own cells used in 3D printed tumors to test treatmentson August 19, 2021 at 11:58 am
The scientists extract “a chunk” of the tumor from the brain of a patient with glioblastoma – an aggressive cancer with a very poor prognosis – and use it to print a model ...
- Cancer-Test Deal Plays Chicken With Regulatorson August 19, 2021 at 8:56 am
Illumina closes its $8 billion acquisition of Grail despite continuing antitrust scrutiny in the U.S. and Europe.
- Cancer patients' own cells used in 3D printed tumours to test treatmentson August 18, 2021 at 4:33 pm
Researchers have used brain cancer patients' own cells in a form of 3D printing material to make a model of their tumour to test the efficacy of potential treatments before using them for real inside ...
- Illumina closes $7.1 bln deal for cancer test maker Grail amid regulatory hurdleson August 18, 2021 at 3:48 pm
Illumina Inc (ILMN.O) has completed its $7.1 billion acquisition of cancer detection test maker Grail Inc (GRAL.O), it said on Wednesday amid challenges posed by the U.S. Federal Trade Commission and ...
- Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Teston August 18, 2021 at 3:38 pm
Illumina, the global leader in DNA sequencing, first announced its intention to acquire GRAIL nearly a year ago, reuniting Illumina with GRAIL four years after it was spun off. GRAIL's Galleri blood ...
- Novel Blood-Based Test Could Bolster MRI-Based Prostate Cancer Screeningon August 13, 2021 at 1:01 pm
Addition of a novel blood test to MRI-targeted biopsy in prostate cancer screening decreased overdetection while maintaining the ability to detect clinically significant cancer, Swedish researchers ...
- New blood test improves prostate cancer screeningon August 13, 2021 at 7:21 am
Researchers at Karolinska Institutet in Sweden recently reported that magnetic resonance imaging (MRI) could reduce overdiagnoses and thereby improve prostate cancer screening. Now, the same research ...
via Bing News